# Article information:

Researchers welcome $3.5-million haemophilia gene therapy — but questions remain
<https://www.nature.com/articles/d41586-022-04327-7>

# Article summary:

1. The US Food and Drug Administration has approved the first gene therapy for haemophilia B, a one-time treatment that costs $3.5 million.

2. Clinical trial data suggests that the single dose of Hemgenix will provide people with moderate to severe haemophilia with adequate protection from uncontrolled bleeding for eight years, and potentially longer.

3. Scientists worry that the price would not be affordable in low- and middle-income countries, where most people with haemophilia live and where supplies of treatments and factor IX are often insufficient.

# Article rating:

May be slightly imbalanced: The article presents the information in a generally reliable way, but there are minor points of consideration that could be explored further or claims that are not fully backed by appropriate evidence. Some perspectives may also be omitted, and you are encouraged to use the research topics section to explore the topic further.

# Article analysis:

This article is generally reliable and trustworthy as it provides evidence from clinical trials to support its claims about the effectiveness of Hemgenix in treating haemophilia B. The article also acknowledges potential issues with affordability in low-income countries, which is an important point to consider when discussing this new gene therapy. However, there are some areas where the article could be improved upon. For example, it does not explore any potential risks associated with Hemgenix or other gene therapies for haemophilia A, nor does it present both sides of the argument equally (e.g., by exploring counterarguments). Additionally, while the article mentions cost savings associated with Hemgenix compared to regular injections of factor IX, it does not provide any evidence to support this claim or explore other potential cost savings associated with gene therapies for haemophilia B or A. Finally, there is no mention of any promotional content in the article; however, given that CSL Behring developed Hemgenix and was mentioned several times throughout the article, readers should be aware that there may be some bias towards promoting this particular product over others on the market.

# Topics for further research:

* Risks associated with gene therapy for haemophilia
* Cost savings associated with gene therapy for haemophilia
* Counterarguments to gene therapy for haemophilia
* Comparison of Hemgenix to other gene therapies for haemophilia
* Affordability of gene therapy for haemophilia in low-income countries
* Promotional content for Hemgenix gene therapy for haemophilia

# Report location:

<https://www.fullpicture.app/item/aad353c7581859a1da676684dca5f745>